Acta Neurologica Scandinavica · 2003 · 17 citations · 19 references
MedicineNeurologyPharmacologyClinical PharmacologyNeuropharmacologySleep MedicineDopaminergic PharmacologyNeurodegenerative Disease PharmacologyNeurodegenerative Disease PharmacotherapyParkinson DiseaseParkinsonian DisordersBromocriptine TreatmentConversion Ratio AnalysisConversion Ratio DesignMedication EfficacyParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyParkinson’s Disease TreatmentSleepiness In Parkinson Disease
INTRODUCTION: Clinicians switch from one dopamine agonist to another for various reasons. However, each change may inadvertently result in certain potential risks such as decreased medication efficacy or new side-effects. OBJECTIVE: We evaluated the tolerability of a switch of bromocriptine to piribedil using two conversion ratios as a primary outcome measure, with motor function as a secondary outcome measure, in patients with mild to moderate Parkinson's disease (PD). METHODS: Twenty consecutive patients with mild to moderate PD (Hoehn and Yahr, stage II-III) on treatment with stable doses of bromocriptine and levodopa were randomized to two groups of 10 patients each, to receive piribedil based on 1:5 or 1:10 conversion ratios. Blinded evaluations were performed: 1) United Parkinson's Diseased Rating Scale (UPDRS) scores both in 'on' and 'off', 2) Open-ended interviews for adverse events, 3) Epworth Sleepiness Scale, 4) Purdue Pegboard assessment during 'on' and 'off', 5) Hand-arm movement test during 'on' and 'off', and 6) Walking test during 'on' and 'off'. RESULTS: Major adverse events included 'sleep attacks' in one patient and minor side-effects included giddiness, nausea, hallucinations, sleepiness and lethargy. However, these were mild and 19 (95%) of the 20 patients completed the study. There was a significant improvement in both the UPDRS 'off' total and motor scores at 1 month compared with baseline for the group on 1:10 ratio. The walking times during the 'off' state at 1 and 2 months were significantly better compared with baseline in the 1:5 group. There were otherwise no significant differences in the rating tests during both 'off' and 'on' states before and after the bromocriptine switch. CONCLUSIONS: We demonstrated that patients with mild to moderate PD who were on relatively low doses of bromocriptine can be safely switched to piribedil based on a conversion ratio of either 1:5 or 1:10. However, the higher conversion ratio has to be carried out with caution in patients with daytime somnolence.
19
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Murray W. Johns · SLEEP · 1991 · 17.2K citations · Full text
Medicine, Neurology, Psychometrics +16
Evaluation of somnolence in Parkinson’s disease: Comparison with age- and sex-matched controls
Eng-King Tan, S.Y. Lum, Stephanie Fook‐Chong et al. · Neurology · 2002 · 168 citations
Medicine, Neurology, Neuroscience +16
A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease
Amos D. Korczyn, Ehrout R. Brunt, Jan Larsen et al. · Neurology · 1999 · 142 citations